Kapila K. Anand - 31 Dec 2025 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Role
Director
Signature
/s/ Amy C. Seidel, as Attorney-in-Fact for Kapila K. Anand
Issuer symbol
ELAN
Transactions as of
31 Dec 2025
Net transactions value
+$8,625
Form type
4
Filing time
05 Jan 2026, 17:35:03 UTC
Previous filing
02 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Anand Kapila K Director C/O ELANCO ANIMAL HEALTH INCORPORATED, 450 ELANCO CIRCLE, INDIANAPOLIS /s/ Amy C. Seidel, as Attorney-in-Fact for Kapila K. Anand 05 Jan 2026 0001679166

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELAN Deferred Stock Units Award $8,625 +381 +4.5% $22.63 8,895 31 Dec 2025 Common Stock 381 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Ms. Anand elected to defer her director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock.
F2 The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan.
F3 The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $22.63 on December 31, 2025.